

# Chemotherapy Induced Peripheral Neuropathy Treatment-North America Market Status and Trend Report 2015-2026

<https://marketpublishers.com/r/C58173AE5EEEN.html>

Date: September 2020

Pages: 135

Price: US\$ 3,480.00 (Single User License)

ID: C58173AE5EEEN

## Abstracts

### Report Summary

Chemotherapy Induced Peripheral Neuropathy Treatment-North America Market Status and Trend Report 2015-2026 offers a comprehensive analysis on Chemotherapy Induced Peripheral Neuropathy Treatment industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole North America and Regional Market Size of Chemotherapy Induced Peripheral Neuropathy Treatment 2015-2019, and development forecast 2020-2026

Main market players of Chemotherapy Induced Peripheral Neuropathy Treatment in North America, with company and product introduction, position in the Chemotherapy Induced Peripheral Neuropathy Treatment market

Market status and development trend of Chemotherapy Induced Peripheral Neuropathy Treatment by types and applications

Cost and profit status of Chemotherapy Induced Peripheral Neuropathy Treatment, and marketing status

Market growth drivers and challenges Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Chemotherapy Induced Peripheral Neuropathy Treatment market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market

disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Chemotherapy Induced Peripheral Neuropathy Treatment industry.

The report segments the North America Chemotherapy Induced Peripheral Neuropathy Treatment market as:

North America Chemotherapy Induced Peripheral Neuropathy Treatment Market:  
Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2015-2026):

United States

Canada

Mexico

North America Chemotherapy Induced Peripheral Neuropathy Treatment Market:  
Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2015-2026):

Calcium Channel  $\beta$ 2-delta Ligands

Antidepressants

Opioids

Others

North America Chemotherapy Induced Peripheral Neuropathy Treatment Market:  
Application Segment Analysis (Consumption Volume and Market Share 2015-2026;  
Downstream Customers and Market Analysis)

Platinum Agents

Taxanes

Vinca Alkaloids

Others

North America Chemotherapy Induced Peripheral Neuropathy Treatment Market:  
Players Segment Analysis (Company and Product introduction, Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume, Revenue, Price and Gross Margin):

Aptinyx Inc

Sova Pharmaceuticals Inc

MAKScientific LLC  
Asahi Kasei Pharma Corp  
PledPharma  
Regenacy Pharmaceuticals  
Kineta Inc  
Nemus Bioscience Inc  
Metys Pharmaceuticals AG  
DermaXon LLC  
Solasia Pharma K.K.  
Krenitsky Pharmaceuticals Inc  
WinSanTor  
PeriphaGen  
Apexian Pharma

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT**

- 1.1 Definition of Chemotherapy Induced Peripheral Neuropathy Treatment in This Report
- 1.2 Commercial Types of Chemotherapy Induced Peripheral Neuropathy Treatment
  - 1.2.1 Calcium Channel  $\alpha$ 2-delta Ligands
  - 1.2.2 Antidepressants
  - 1.2.3 Opioids
  - 1.2.4 Others
- 1.3 Downstream Application of Chemotherapy Induced Peripheral Neuropathy Treatment
  - 1.3.1 Platinum Agents
  - 1.3.2 Taxanes
  - 1.3.3 Vinca Alkaloids
  - 1.3.4 Others
- 1.4 Development History of Chemotherapy Induced Peripheral Neuropathy Treatment
- 1.5 Market Status and Trend of Chemotherapy Induced Peripheral Neuropathy Treatment 2015-2026
  - 1.5.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Status and Trend 2015-2026
  - 1.5.2 Regional Chemotherapy Induced Peripheral Neuropathy Treatment Market Status and Trend 2015-2026

### **CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Chemotherapy Induced Peripheral Neuropathy Treatment in North America 2015-2019
- 2.2 Consumption Market of Chemotherapy Induced Peripheral Neuropathy Treatment in North America by Regions
  - 2.2.1 Consumption Volume of Chemotherapy Induced Peripheral Neuropathy Treatment in North America by Regions
  - 2.2.2 Revenue of Chemotherapy Induced Peripheral Neuropathy Treatment in North America by Regions
- 2.3 Market Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment in North America by Regions
  - 2.3.1 Market Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment in

United States 2015-2019

2.3.2 Market Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment in Canada 2015-2019

2.3.3 Market Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment in Mexico 2015-2019

2.4 Market Development Forecast of Chemotherapy Induced Peripheral Neuropathy Treatment in North America 2020-2026

2.4.1 Market Development Forecast of Chemotherapy Induced Peripheral Neuropathy Treatment in North America 2020-2026

2.4.2 Market Development Forecast of Chemotherapy Induced Peripheral Neuropathy Treatment by Regions 2020-2026

## **CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole North America Market Status by Types

3.1.1 Consumption Volume of Chemotherapy Induced Peripheral Neuropathy Treatment in North America by Types

3.1.2 Revenue of Chemotherapy Induced Peripheral Neuropathy Treatment in North America by Types

3.2 North America Market Status by Types in Major Countries

3.2.1 Market Status by Types in United States

3.2.2 Market Status by Types in Canada

3.2.3 Market Status by Types in Mexico

3.3 Market Forecast of Chemotherapy Induced Peripheral Neuropathy Treatment in North America by Types

## **CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of Chemotherapy Induced Peripheral Neuropathy Treatment in North America by Downstream Industry

4.2 Demand Volume of Chemotherapy Induced Peripheral Neuropathy Treatment by Downstream Industry in Major Countries

4.2.1 Demand Volume of Chemotherapy Induced Peripheral Neuropathy Treatment by Downstream Industry in United States

4.2.2 Demand Volume of Chemotherapy Induced Peripheral Neuropathy Treatment by Downstream Industry in Canada

4.2.3 Demand Volume of Chemotherapy Induced Peripheral Neuropathy Treatment by Downstream Industry in Mexico

4.3 Market Forecast of Chemotherapy Induced Peripheral Neuropathy Treatment in North America by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT**

5.1 North America Economy Situation and Trend Overview

5.2 Chemotherapy Induced Peripheral Neuropathy Treatment Downstream Industry Situation and Trend Overview

## **CHAPTER 6 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA**

6.1 Sales Volume of Chemotherapy Induced Peripheral Neuropathy Treatment in North America by Major Players

6.2 Revenue of Chemotherapy Induced Peripheral Neuropathy Treatment in North America by Major Players

6.3 Basic Information of Chemotherapy Induced Peripheral Neuropathy Treatment by Major Players

6.3.1 Headquarters Location and Established Time of Chemotherapy Induced Peripheral Neuropathy Treatment Major Players

6.3.2 Employees and Revenue Level of Chemotherapy Induced Peripheral Neuropathy Treatment Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Aptinyx Inc

7.1.1 Company profile

7.1.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment Product

7.1.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of Aptinyx Inc

7.2 Sova Pharmaceuticals Inc

### 7.2.1 Company profile

### 7.2.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment

#### Product

### 7.2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of Sova Pharmaceuticals Inc

## 7.3 MAKScientific LLC

### 7.3.1 Company profile

### 7.3.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment

#### Product

### 7.3.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of MAKScientific LLC

## 7.4 Asahi Kasei Pharma Corp

### 7.4.1 Company profile

### 7.4.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment

#### Product

### 7.4.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of Asahi Kasei Pharma Corp

## 7.5 PledPharma

### 7.5.1 Company profile

### 7.5.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment

#### Product

### 7.5.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of PledPharma

## 7.6 Regenacy Pharmaceuticals

### 7.6.1 Company profile

### 7.6.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment

#### Product

### 7.6.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of Regenacy Pharmaceuticals

## 7.7 Kineta Inc

### 7.7.1 Company profile

### 7.7.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment

#### Product

### 7.7.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of Kineta Inc

## 7.8 Nemus Bioscience Inc

### 7.8.1 Company profile

### 7.8.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment

#### Product

7.8.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of Nemus Bioscience Inc

7.9 Metys Pharmaceuticals AG

7.9.1 Company profile

7.9.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment Product

7.9.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of Metys Pharmaceuticals AG

7.10 DermaXon LLC

7.10.1 Company profile

7.10.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment Product

7.10.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of DermaXon LLC

7.11 Solasia Pharma K.K.

7.11.1 Company profile

7.11.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment Product

7.11.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of Solasia Pharma K.K.

7.12 Krenitsky Pharmaceuticals Inc

7.12.1 Company profile

7.12.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment Product

7.12.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of Krenitsky Pharmaceuticals Inc

7.13 WinSanTor

7.13.1 Company profile

7.13.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment Product

7.13.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of WinSanTor

7.14 PeriphaGen

7.14.1 Company profile

7.14.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment Product

7.14.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of PeriphaGen

7.15 Apexian Pharma



- 7.15.1 Company profile
- 7.15.2 Representative Chemotherapy Induced Peripheral Neuropathy Treatment Product
- 7.15.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin of Apexian Pharma

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT**

- 8.1 Industry Chain of Chemotherapy Induced Peripheral Neuropathy Treatment
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT**

- 9.1 Cost Structure Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
- 9.2 Raw Materials Cost Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
- 9.3 Labor Cost Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
- 9.4 Manufacturing Expenses Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

## 12.1 Methodology/Research Approach

### 12.1.1 Research Programs/Design

### 12.1.2 Market Size Estimation

### 12.1.3 Market Breakdown and Data Triangulation

## 12.2 Data Source

### 12.2.1 Secondary Sources

### 12.2.2 Primary Sources

## 12.3 Reference

## I would like to order

Product name: Chemotherapy Induced Peripheral Neuropathy Treatment-North America Market Status and Trend Report 2015-2026

Product link: <https://marketpublishers.com/r/C58173AE5EEEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C58173AE5EEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

